BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/14/2023 5:08:46 AM | Browse: 225 | Download: 984
 |
Received |
|
2023-09-05 08:34 |
 |
Peer-Review Started |
|
2023-09-05 08:34 |
 |
First Decision by Editorial Office Director |
|
2023-09-15 22:51 |
 |
Return for Revision |
|
2023-09-15 22:51 |
 |
Revised |
|
2023-10-09 03:34 |
 |
Publication Fee Transferred |
|
|
 |
Second Decision by Editor |
|
2023-11-01 07:44 |
 |
Second Decision by Editor-in-Chief |
|
|
 |
Final Decision by Editorial Office Director |
|
2023-11-08 21:40 |
 |
Articles in Press |
|
2023-11-08 21:40 |
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
2023-12-06 14:55 |
 |
Publish the Manuscript Online |
|
2023-12-14 05:08 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Immunology |
| Manuscript Type |
Basic Study |
| Article Title |
Combined TIM-3 and PD-1 blockade restrains hepatocellular carcinoma development by facilitating CD4+ and CD8+ T cell-mediated antitumor immune responses
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Xu-Sheng Zhang, Hong-Cai Zhou, Peng Wei, Long Chen, Wei-Hu Ma, Lin Ding, Shi-Cai Liang and Ben-Dong Chen |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| First-Class Discipline Construction Founded Project of Ningxia Medical University and the School of Clinical Medicine |
2020008 |
|
| Corresponding Author |
Ben-Dong Chen, MD, Doctor, Doctor, Department of Hepatobiliary Surgery, The General Hospital of Ningxia Medical University, No. 804 Shengli Street, Yinchuan 750004, Ningxia Hui Autonomous Region, China. bendong8511@nyfy.com.cn |
| Key Words |
Hepatocellular carcinoma; T cell immunoglobulin and mucin domain-containing protein 3; Programmed cell death protein 1; CD4+ T cells; CD8+ T cells |
| Core Tip |
This study investigated the effects of combined blockade of T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3) and programmed cell death protein 1 (PD-1) on tumor development in a hepatocellular carcinoma (HCC) mouse model. We showed that combined TIM-3 and PD-1 blockade had more substantial inhibitory effects on tumor growth in mice compared with individual blockade. The combined therapy increased T cell infiltration and ameliorated CD4+ and CD8+ T cell exhaustion in HCC mouse model. Our findings proposed an effective immunotherapy and may provide more treatment options for HCC patients. |
| Publish Date |
2023-12-14 05:08 |
| Citation |
Zhang XS, Zhou HC, Wei P, Chen L, Ma WH, Ding L, Liang SC, Chen BD. Combined TIM-3 and PD-1 blockade restrains hepatocellular carcinoma development by facilitating CD4+ and CD8+ T cell-mediated antitumor immune responses. World J Gastrointest Oncol 2023; 15(12): 2138-2149 |
| URL |
https://www.wjgnet.com/1948-5204/full/v15/i12/2138.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v15.i12.2138 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.